Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature

Other authors

Institut Català de la Salut

[Araujo-Castro M] Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Madrid, Spain. Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain. [Marazuela M] Department of Endocrinology and Nutrition, Hospital Universitario La Princesa, Madrid, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER GCV14/ER/12), Monforte de Lemos Avenue, Madrid, Spain. [Puig-Domingo M] Department of Endocrinology and Nutrition, Department of Medicine, Germans Trias i Pujol Research Institute and Hospital, Universitat Autònoma de Barcelona, Badalona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras CIBERER G747, Madrid, Spain. [Biagetti B] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Reference Networks (ERN), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERDEM (ISCIII), Universitat Autònoma de Barcelona, Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2023-10-05T12:41:23Z

2023-10-05T12:41:23Z

2023-09-12



Abstract

Acromegaly; Dopamine receptor; Pituitary neuroendocrine tumors


Acromegalia; Receptor de dopamina; Tumores neuroendocrinos hipofisarios


Acromegàlia; Receptor de dopamina; Tumors neuroendocrins hipofisaris


Prolactin (PRL) and growth hormone (GH) are peptide hormones that bind to the class 1 cytokine receptor superfamily, a highly conserved cell surface class of receptors. Both hormones control their own secretion via a negative autocrine loop in their own mammosomatotroph, lactotroph or somatotroph. In this regard, GH and PRL are regulated by similar signaling pathways involving cell growth and hormone secretion. Thus, GH and PRL dysregulation and pituitary neuroendocrine tumor (PitNET) development may have common pathogenic pathways. Based on cell linage, lactotroph and somatotroph PitNETs come from pituitary-specific POU-class homeodomain transcription factor (Pit-1). Mammosomatotroph and plurihormonal PitNETs are a unique subtype of PitNETs that arise from a single-cell population of Pit-1 lineage. In contrast, mixed somatotroph–lactotroph PitNETs are composed of two distinct cell populations: somatotrophs and lactotrophs. Morphologic features that distinguish indolent PitNETs from locally aggressive ones are still unidentified, and no single prognostic parameter can predict tumor aggressiveness or treatment response. In this review, we aim to explore the latest research on lactotroph and somatotroph PitNETs, the molecular mechanisms involved in PRL and GH axis regulation and the signaling pathways involved in their aggressiveness, particularly focused on mammosomatotroph and mixed subtypes. Finally, we summarize epidemiological, clinical, and radiological features of these exceptional tumors. We aim to shed light, from basic to clinical settings, on new perspectives and scientific gaps in this field.


This research has been funded by the Spanish Society of Endocrinology and Nutrition (SEEN) with the SEEN Foundation Award to the Junior Scholarship Research Project 2022 [Impact of prolactin cosecretion on the expression of molecular markers and in response to treatment with somatostatin analogues and agonists dopaminergic in patients with acromegaly].

Document Type

Article


Published version

Language

English

Publisher

MDPI

Related items

International Journal of Molecular Sciences;24(18)

https://doi.org/10.3390/ijms241814002

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)